These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8095981)

  • 1. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy.
    Holodniy M; Katzenstein D; Winters M; Montoya J; Shafer R; Kozal M; Ragni M; Merigan TC
    J Acquir Immune Defic Syndr (1988); 1993 Apr; 6(4):366-9. PubMed ID: 8095981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.
    Holodniy M; Mole L; Margolis D; Moss J; Dong H; Boyer E; Urdea M; Kolberg J; Eastman S
    J Virol; 1995 Jun; 69(6):3510-6. PubMed ID: 7745698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
    Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N
    AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
    Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
    AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ; Kroodsma K; Winters MA; Shafer RW; Efron B; Katzenstein DA; Merigan TC
    Ann Intern Med; 1994 Aug; 121(4):263-8. PubMed ID: 7518658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group.
    Pellegrin I; Izopet J; Reynes J; Denayrolles M; Montes B; Pellegrin JL; Massip P; Puel J; Fleury H; Segondy M
    AIDS; 1999 Sep; 13(13):1705-9. PubMed ID: 10509572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
    An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
    Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
    AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine.
    Katzenstein DA; Winters M; Bubp J; Israelski D; Winger E; Merigan TC
    J Infect Dis; 1994 Feb; 169(2):416-9. PubMed ID: 7906292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
    Horneff G; Adams O; Wahn V
    AIDS; 1998 Mar; 12(5):489-94. PubMed ID: 9543447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.